2018 will be the year gene therapies come into their own. After decades on unfulfilled potential, this space is gaining tangible momentum, particularly in addressing the significant unmet need in a range of rare diseases.
Gene Therapy for Rare Disorders 2018 is the uniquely focused conference that will unite the leaders in this field to identify and discuss the critical factors that will influence genetic treatments most significantly in the near future.
Bringing together leading experts from innovative biotechs, large pharma, academia and key service provider companies, Gene Therapy for Rare Disorders 2018 will present a comprehensive insight into the cutting edge progress of gene therapies combatting rare disease.
Companies confirmed to attend include:
Spark Therapeutics – FDA – uniQure – Pfizer – GSK – Rocket Pharma – Sanofi-Genzyme
Bluebird Bio – Adverum – Aquilo Capital Management – REGENXBIO
Adrenas Therapeutics – BioMarin – Bioverativ – Dimension Therapeutics
NORD – Milo – Shire – Voyager – AvroBio – Burns & Levinson LLP – Harvard Medical School
Noah’s Hope – Sarepta Therapeutics – University of Massachusetts Medical School
Solid Biosciences – Atlas Venture – Voisin Consulting – Abeona Therapeutics – Agilis
Join your colleagues at Gene Therapy for Rare Disorders 2018 to accelerate the progress of the next generation of gene therapies that show improved efficacy, enhanced safety and commercial viability.
Download the full program to see what will be discussed.